AACR 2022 | Chemokine-modulating infusion for patients with recurrent breast cancer

Pawel Kalinski, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses promising findings of a Phase I clinical trial (NCT03599453), which assessed a chemokine-modulating infusion in patients with triple-negative breast cancer. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.